{"id":"W2086572083","doi":"10.1212/wnl.0b013e3181c67808","title":"A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease","year":2009,"lang":"en","type":"letter","venue":"Neurology","topic":"Alzheimer's disease research and treatments","field":"Medicine","cited_by":739,"is_retracted":false,"has_abstract":true,"ca_institutions":"Women's Health Research Institute","funders":"National Center for Research Resources; National Institute of Neurological Disorders and Stroke; National Institute of Mental Health; National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; U.S. Public Health Service; National Institute for Health and Care Research; Pfizer","keywords":"Medicine; Internal medicine; Asymptomatic; Placebo; Cognitive decline; Dementia; Population; Disease; Gastroenterology; Clinical endpoint; Oncology; Pathology; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001228384,0.0004816413,0.00107672,0.0007746402,0.00005050458,0.00001585753,0.0002316938,0.0005311182,0.0001617611],"category_scores_gemma":[0.0002216592,0.0004304698,0.0003349966,0.000305203,0.000110332,0.00006078743,0.00009818716,0.001513209,0.0001242902],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004973917,"about_ca_system_score_gemma":0.0005104914,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001627182,"about_ca_topic_score_gemma":0.00001832744,"domain_scores_codex":[0.9966,0.0003820485,0.0006099629,0.000884675,0.0006115498,0.0009117758],"domain_scores_gemma":[0.998079,0.0002607377,0.0001636239,0.0007864176,0.0001009221,0.0006092889],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6768011,0.006942474,0.0009578262,0.0001620664,0.00411952,0.04119469,0.00006611485,0.0000459169,0.0000545931,0.000005340233,0.2642764,0.00537395],"study_design_scores_gemma":[0.7681836,0.05721936,0.008431206,0.0003643463,0.006563197,0.0001591376,0.000002716902,0.004402043,0.0003930504,0.0004385887,0.1525824,0.001260346],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.5424168,0.004070027,0.00000806515,0.4469619,0.0005364273,0.004973766,0.0004939132,0.00009084356,0.0004482335],"genre_scores_gemma":[0.6797743,0.0001577334,0.0000658748,0.316955,0.001647158,0.0003270672,0.0009338742,0.00009686242,0.0000420827],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1373576,"threshold_uncertainty_score":0.9998147,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06927806411358578,"score_gpt":0.3671225997386713,"score_spread":0.2978445356250856,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}